WallStSmart

agilon health Inc (AGL)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 954% more annual revenue ($61.37B vs $5.82B). AZN leads profitability with a 17.0% profit margin vs -6.1%. AZN earns a higher WallStSmart Score of 65/100 (B-).

AGL

Hold

37

out of 100

Grade: F

Growth: 7.3Profit: 2.5Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 1.54

AZN

Strong Buy

65

out of 100

Grade: B-

Growth: 5.3Profit: 8.0Value: 6.7Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for AGL.

AZNUndervalued (+20.4%)

Margin of Safety

+20.4%

Fair Value

$196.68

Current Price

$156.45

$40.23 discount

UndervaluedFair: $196.68Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AGL2 strengths · Avg: 9.5/10
EPS GrowthGrowth
301.0%10/10

Earnings expanding 301.0% YoY

Debt/EquityHealth
0.159/10

Conservative balance sheet, low leverage

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$243.86B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
20.8%9/10

Every $100 of equity generates 21 in profit

Operating MarginProfitability
23.5%8/10

Strong operational efficiency at 23.5%

Free Cash FlowQuality
$2.13B8/10

Generating 2.1B in free cash flow

Areas to Watch

AGL4 concerns · Avg: 3.5/10
Price/BookValuation
8.9x4/10

Trading at 8.9x book value

Altman Z-ScoreHealth
1.544/10

Distress zone — elevated risk

Market CapQuality
$1.57B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.7%3/10

Operating margin of 0.7%

AZN2 concerns · Avg: 3.0/10
EPS GrowthGrowth
2.5%4/10

2.5% earnings growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AGL

The strongest argument for AGL centers on EPS Growth, Debt/Equity.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.40 suggests the stock is reasonably priced for its growth.

Bear Case : AGL

The primary concerns for AGL are Price/Book, Altman Z-Score, Market Cap.

Bear Case : AZN

The primary concerns for AZN are EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

AGL profiles as a turnaround stock while AZN is a mature play — different risk/reward profiles.

AGL carries more volatility with a beta of 3.05 — expect wider price swings.

AZN is growing revenue faster at 6.4% — sustainability is the question.

AZN generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (65/100 vs 37/100), backed by strong 17.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

agilon health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

agilon health, inc. The company is headquartered in Long Beach, California.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?